Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression
Michal Schnaider Beeri1, Joshua Sonnen2
1From the Department of Psychiatry (M.S.B.), The Icahn School of Medicine at Mount Sinai, New York, NY; The Joseph Sagol Neuroscience Center (M.S.B.), Sheba Medical Center, Ramat Gan, Israel; and Department of Pathology (J.S.), University of Utah Medical Center, Salt Lake City, UT. michal.beeri@mssm.edu.
Neurology
|January 29, 2016
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Neural Regulation
44.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.7K
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K


